fda compounding tirzepatide pharmacy BPI Labs The FDA says it's standing

Medical Weight Loss with Semaglutide Our medical weight loss programs are tailored to assist individuals facing challenges with conventional weight loss methods such as diet and exercise

Semaglutide is unlikely to cause liver damage and may even reduce liver fat, though it's not a treatment for liver conditions

Studied in the context of: Promoting significant weight loss (clinical trials showed over 20% body weight reduction in some patients) Dramatically improving insulin sensitivity and blood sugar control Increasing energy expenditure by enhancing lipolysis (fat breakdown) and fat oxidation Suppressing appetite and cravings, leading to reduced caloric intake Slowing gastric emptying, which prolongs fullness and further curbs appetite Enhancing glucose-dependent insulin secretion (more insulin release when blood sugar is high) Reducing glucagon levels and hepatic glucose output, helping to lower fasting blood glucose Improving cardiometabolic health markers (like lowering liver fat and possibly improving cholesterol profiles)

Unlike FDA-approved medications (e.g., Wegovy, Ozempic, Zepbound), compounded alternatives lack agency review for safety, quality, and efficacy

If you recently started Wegovy, you may notice slower digestion